In Vivo Delivery of Polycistronic mRNA-LNPs Reprograms CAR-T Cells for Metastatic TNBC Therapy

Dr. Kim's research focuses on developing next-generation engineered immune cell therapies and biomaterial-based technologies to treat disease. For cancer, her laboratory employs synthetic biology approaches to design immune cell therapies that can resist immunosuppression and more effectively target the tumor microenvironment. The Kim lab is also exploring in vivo engineering strategies using mRNA–lipid nanoparticles to program immune cells directly within the body, with the goal of making therapies more affordable and rapidly accessible to patients. By integrating immune cell engineering, biomaterials, and diverse testing platforms, Dr. Kim's team aims to overcome key barriers in immunotherapy and advance innovative treatments toward clinical application.